IP Library Granted Patent US 9,447,405
Granted Patent B2
US 9,447,405 · App. 14/181,241 · Granted Sep 20, 2016

Regulation of specific spinal neurons regulating pain transmission via chimeric toxins

Inventors: Eric A. Johnson (Madison, WI); Sabine Pellett (Madison, WI); William H. Tepp (Stoughton, WI); Tony L. Yaksh (San Diego, CA); Marc Marino (San Diego, CA); Qinghao Xu (San Diego, CA)
Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
C12N9/96A61K38/164A61K38/4893A61K47/48238C07K7/22C07K14/33C07K14/57545C07K14/70C07K14/72C07K2319/01C07K2319/33C07K2319/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,447,405
App. No.
14/181,241
Granted
Sep 20, 2016
Kind
B2
Abstract

A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.

Claims (13)

1. A chimeric toxin comprising

(a) a peptide ligand specifically targeting neurons involved in pain processing; wherein the ligand is Substance P (SEQ ID NO:1), and

(b) a clostridial neurotoxin light chain, wherein the light chain is botulinum toxin type A light chain,

wherein the ligand is linked to the light chain to form a chimeric toxin, and wherein the chimeric toxin does not comprise a translocation domain.

2. The toxin of claim 1 , wherein the link is a covalent bond.

3. The toxin of claim 1 , wherein the covalent bond comprises a disulfide linker.

4. A pharmaceutical formulation comprising

(a) a therapeutically effective amount of a chimeric toxin comprising

(i) a peptide ligand specifically targeting neurons involved in pain processing, wherein the ligand is substance P (SEQ ID NO:1); and

(ii) a clostridial neurotoxin light chain, wherein the light chain is type A light chain,

wherein the ligand is linked to the light chain to form a chimeric toxin, and wherein the chimeric toxin does not comprise a translocation domain;

and

(b) a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2014
From: JOHNSON, ERIC; TEPP, WILLIAM; PELLETT, SABINE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 032811/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2014
From: YAKSH, TONY L.; MARINO, MARC; XU, QINGHAO
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 032811/0964 →
CONFIRMATORY LICENSE Recorded Feb 27, 2014
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032362/0249 →
Continuity (2)
Provisional Application 61775116 · Mar 8, 2013
Related Publication 20140255376A1 · Sep 11, 2014